The EC-EUnetHTA Forum "European cooperation on HTA: what's next?" co-organised by the European Commission and the EUnetHTA Joint Action 3 was the first meeting between all 79 EUnetHTA partner organisations and the broader HTA stakeholder community.
The Forum entitled “European Cooperation on HTA: What’s next?” is jointly organized by the European Commission and EUnetHTA and EC on the 21st of October 2016 in Brussels (The Square conference center).
On the 7th June 2016, a technical meeting was held in Paris, hosted by Haute Autorité de Santé (HAS, EUnetHTA Work Package 5 lead). The participants of this meeting not only included all EUnetHTA Joint Action 3 WP leads, but also representatives from industry (pharmaceutical), European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Agency (EMA), HTA agencies and the European Commission.
The Dutch National Health Care Institute and the European Commission signed the Grant Agreement on the 25th of August 2016. Within 30 days all organisations need to sign in order to join the creation of sustainable HTA network. Then Joint Action 3 will start officially.
The European Medicines Agency (EMA) and the European network for Health Technology Assessment (EUnetHTA) published today a report on their implementation of the joint work plan covering the period between November 2012 and December 2015.
Aims Joint Action 3 aims to define and implement a sustainable model for the scientific and technical cooperation on Health Technology Assessment (HTA) in Europe. The voluntary cooperation within and between national and regional HTA Bodies is essential in this joint action.
A joint assessment is a structured information for rapid or full/comprehensive HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes (Based on definitions from the HTA Network Strategy (page 24) and the EUnetHTA Recommendations (page 6, footnote 8))